Pfizer Inc.
Aminopyrimidinyl compounds

Abstract:

A compound having the structure: ##STR00001## or an acceptable salt thereof, wherein X is N or CR, where R is hydrogen, alkyl, etc.; A is selected from the group consisting of a bond, C.dbd.O, --SO.sub.2--, etc.; A' is selected from the group consisting of a bond, C.dbd.O, etc.; Z is --(CH.sub.2).sub.h-- or a bond, etc.; R.sub.1 and R.sub.1' are independently selected from the group consisting of hydrogen, alkyl, etc.; R.sub.2 is selected from hydrogen, alkyl, etc.; R.sub.3 is selected from the group consisting of hydrogen, and amino; R.sub.4 is monocyclic or bicyclic, etc.; R.sub.5 is independently selected from hydrogen, alkyl, etc.; h, j, k, m, n and q are integers as defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.